BALDRY MARK (Chief Commercial Officer) sold 23.7% of their position (29.16K shares) of X4 PHARMACEUTICALS, INC on the open market
Open‑market sale worth $13.2K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 1/27/2025ACC: 0001628280-25-002707
Officer· Chief Commercial Officer
Since Nov 2022
+45.61K
Net shares
Net buyer
$13.2K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
74.77K acquired · 29.16K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+74.77K
Price / share
—
Trade value
—
% of position
154.1%
1/23/2025
48.51K→123.28K
Common Stock
Direct
Shares
−29.16K
Price / share
$0.45
Trade value
$13.24K
% of position
23.7%
1/24/2025
123.28K→94.12K
Total
Net shares
+45.61K
Net value
-$13.24K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/23/2025 | A · Award | +74.77K | — | — | 154.1% | 48.51K | 123.28K |
| Common Stock Direct | 1/24/2025 | S · Sale | −29.16K | $0.45 | $13.24K | 23.7% | 123.28K | 94.12K |
| Total | +45.61K | -$13.24K | ||||||
Derivative Transactions0
No derivative transactions reported